Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193427 · ClinicalTrials.gov registry record · Phase 2
Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT00193427 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 75 participants.
The verdict
NCT00193427, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the concurrent use with radiation therapy at these weekly doses may produce not only radio-sensitization, but also considerable antitumor efficacy.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Gemcitabine
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193427
The ClinicalTrials.gov registry entry for NCT00193427 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00193427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00193427 about?
NCT00193427 is a clinical study titled "Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer". This trial is designed to study the role of docetaxel/gemcitabine, an active and relatively non-toxic combination in advanced NSCLC. This study will help to better define optimal preoperative regimens for patients with resectable NSCLC. Since both of these drugs are potent radio-sensitizers, the con...
What is the current status of trial NCT00193427?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2004-04. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00193427?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Gemcitabine (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT00193427?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.